



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/538,370

Filing Date

June 13, 2005

First Named Inventor

EMTAGE, Peter C.R.

Art Unit

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

HYS-67PCT/US

ENCLOSURES (Check all that apply)☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/
Incomplete Application☐Reply to Missing Parts
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a
Provisional Application☐Power of Attorney, Revocation
Change of Correspondence Address☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐ Landscape Table on CD

Remarks

☐

After Allowance Communication to TC

☐Appeal Communication to Board
of Appeals and Interferences☐Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Other Enclosure(s) (please identify
below):Form PTO 1449
Copies of 23 References
Return Postcard**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

NUVELO, Inc.

Signature

Renee S. Polizotto

Printed name

Renee S. Polizotto

Date

September 9, 2005

Reg. No.

53,474

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Steven C Garland

Typed or printed name

Steven C. Garland

Date

September 9, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



JC06 Rec'd PCT/PTO 12 SEP 2005

PATENT

Docket No.: HYS-67PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Peter C.R. Emtage
Serial No: 10/538,370
Filed: June 13, 2005
For: METHODS OF THERAPY AND
DIAGNOSIS USING
TARGETING OF CELLS THAT
EXPRESS LAX

**CERTIFICATE OF MAILING
UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, with sufficient postage as first class mail in an envelope addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: September 9, 2005

Type or Print Name of Person Mailing: Steven C. Garland


Signature of Person Mailing

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by Applicants in connection with the above-identified application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents C1-C23 cited on the PTO-1449 submitted herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. § 102 or § 103.

In accordance with 37 C.F.R. §1.98(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted within three months of filing the above-identified patent application. However, the Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169.

Respectfully submitted,

Date: September 9, 2005

By: 
Renée S. Polizotto, Ph.D.
Agent for Applicants
Reg. No. 53,474
Customer No. 34285
Nuvelo, Inc..
675 Almanor Avenue
Sunnyvale, CA 94085
Tel.: (408) 215.4000
Fax: (408) 524.8145



SHEET 1 of 3

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

HYS-67PCT/US

Serial No.

10/538,370

**INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)

Applicant

Peter C.R. Emtage

Filing Date

June 13, 2005

Group

TBD

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclas s	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclas s	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	AMLOT <i>et al.</i> , "A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of a B-cell lymphoma resistant to conventional therapy," <i>Blood</i> 82(9):2624-2633 (1993).
	C2	ANDREAKOS <i>et al.</i> , "Monoclonal antibodies in immune and inflammatory diseases," <i>Curr. Opin. Biotechnol.</i> 13:615-620 (2002).
	C3	BERGER <i>et al.</i> , "Therapeutic applications of monoclonal antibodies," <i>Am. J. Med. Sci.</i> 324(21):14-30 (2002).
	C4	BIRNBAUM <i>et al.</i> , "Insulin-like growth factor-binding protein-3 expression and secretion by cultures of human prostate epithelial cells and stromal fibroblasts," <i>J. Endocrinol.</i> 141:535-540 (1994).
	C5	CRETICOS, "The consideration of immunotherapy in the treatment of allergic asthma," <i>Ann. Allergy Asthma Immunol.</i> 87(Suppl):13-27 (2001).
	C6	DAEMON <i>et al.</i> , "Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation," <i>Endocrinology</i> 139:3456-3464 (1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. HYS-67PCT/US	Serial No. 10/538,370
INFORMATION DISCLOSURE STATEMENT		Applicant Peter C.R. Emtage	
		Filing Date June 13, 2005	Group TBD
(Use several sheets if necessary)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C7	FONG, "Immunotherapy in autoimmune diseases," <i>Ann. Acad. Med. Singapore</i> 31:702-706 (2002).	
C8	HOFMANN and STOFFEL, "A database of membrane spanning protein segments," <i>Biol. Chem. Hoppe-Seyler</i> 374:166 (1993).	
C9	HORNICK <i>et al.</i> , "Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties," <i>Blood</i> 89(12):4437-4447 (1997).	
C10	HSU <i>et al.</i> , "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," <i>Nat. Med.</i> 2(1):52-58 (1996).	
C11	HSU <i>et al.</i> , "Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial," <i>Blood</i> 9(1):3129-3135 (1997).	
C12	JIANG <i>et al.</i> , "In vitro effects of HgCl ₂ on murine lymphocytes. I: Preferable activation of CD4 ⁺ T cells in a responder strain," <i>J. Immunol.</i> 154:3138-3146 (1995).	
C13	MALONEY <i>et al.</i> , "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> 84(8):2457-2466 (1994).	
C14	MALONEY <i>et al.</i> , "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines," <i>Blood</i> 88(Suppl):637a (1996).	
C15	MALONEY <i>et al.</i> , "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> 90(6):2188-2195 (1997).	
C16	MARTIN <i>et al.</i> , "CD84 functions as a homophilic adhesion molecule and enhances IFN- γ secretion: adhesion is mediated by Ig-like domain 1," <i>J. Immunol.</i> 167:3668-3676 (2001).	
C17	OZAKI <i>et al.</i> , "Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24" <i>Blood</i> 90(8):3179-3186 (1997).	
C18	PRESS <i>et al.</i> , "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphoma," <i>Blood</i> 69(2):584-591 (1987).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. HYS-67PCT/US	Serial No. 10/538,370
INFORMATION DISCLOSURE STATEMENT		Applicant Peter C.R. Emtage	
		Filing Date June 13, 2005	Group TBD
<i>(Use several sheets if necessary)</i>			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C19	REHWALD <i>et al.</i> , "Treatment of relapsed CD20 ⁺ Hodgkin's lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin lymphoma study group," <i>Blood</i> 101(2):420-424 (2003).	
C20	SIMPSON <i>et al.</i> , "Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR," <i>Molec. Vision</i> 6:178-183 (2000).	
C21	SINGH <i>et al.</i> , "The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma," <i>Vaccine</i> 20:1400-1411 (2002).	
C22	SPRENGER <i>et al.</i> , "Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer," <i>Cancer Res.</i> 59:2370-2375 (1999).	
C23	ZHU <i>et al.</i> , "Molecular cloning of a novel gene encoding a membrane associated adaptor protein (LAX) in lymphocyte signaling," <i>J. Biol. Chem.</i> 277(48):46151-46158 (2002).	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	